Discover strategies for developing robust pharmacokinetic assays for complex bispecific antibodies.

Accurate pharmacokinetic (PK) assessment of bispecific antibodies requires sensitive, reliable analytical methods capable of addressing unique molecular complexities. This poster highlights the development and validation of an electrochemiluminescence (ECL)-based bridging immunoassay for the biparatopic antibody TNB-738, demonstrating approaches for optimizing assay performance to support clinical development.

Key highlights include:

• Development and validation of an ECL-based bridging immunoassay for a bispecific antibody
• Strategies for improving assay sensitivity, precision, and robustness
• Considerations for overcoming analytical challenges associated with complex antibody therapeutics
• Evaluation of assay performance to support pharmacokinetic analysis
• Practical insights for developing fit-for-purpose PK assays for next-generation biologics

As bispecific antibodies continue to advance through clinical development, robust bioanalytical methods are essential for generating reliable pharmacokinetic data. Learn how thoughtful assay design and optimization can support successful PK assessments for complex biologic therapies.